Meeting
2022 ASCO Annual Meeting
Characterization of alpelisib-associated hyperglycemia in metastatic breast cancer.
Authors
Sherry Shen
Memorial Sloan Kettering Cancer Center, New York, NY
Sherry Shen , Yuan Chen , Andrea Carpio , Cassandra Chang , Neil M. Iyengar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1016)
DOI
10.1200/JCO.2022.40.16_suppl.1016
Abstract #
1016
Poster Bd #
394
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The Amelia-1 study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant and alpelisib in patients with advanced breast cancer at risk for alpelisib-induced hyperglycemia.
First Author: Peter Cornelius
Poster
2023 ASCO Annual Meeting
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).
First Author: Dejan Juric
Poster
2023 ASCO Annual Meeting
Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.
First Author: Stephen Chia
Poster
2022 ASCO Quality Care Symposium
Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).
First Author: Emily J. Gallagher